RCT | Efficacy and safety of bimekizumab in axial spondyloarthritis

Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials – Annals of the Rheumatic Diseases

Related:

Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE) – The Lancet

Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL) – The Lancet

Bimekizumab versus Secukinumab in Plaque Psoriasis – New England Journal of Medicine

Bimekizumab versus Adalimumab in Plaque Psoriasis – New England Journal of Medicine